Chemotherapy in Infants with Acute Lymphoblastic Leukemia

Status: open

AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND#TBD, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement

Treatment for Leukemia in Infants

Contact Us Or call 251-405-5121

Description

This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.

Sponsors

This trial is sponsored by Children's Oncology Group.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.